Creative Biolabs has become an undisputed global leader in the rapidly emerging market of in vitro diagnostics (IVD) antibodies. With vast experience and professional scientists, we can efficiently provide custom development service of IVD antibodies for miR-499 marker in a timely manner. Our IVD antibodies are available for diagnosis of a variety of diseases, including myocardial infarction (MI) and non-small cell lung cancer (NSCLC).
MicroRNAs (miRNAs) are a group of endogenous small RNAs that are 21–25 nucleotides in length. They can bind to the 3' UTR sites in mRNAs of protein-coding genes to down regulate their expression and serve essential roles in a variety of physiological and pathologic processes. miRNAs are also shown to act an important role in cardiac development, and the expression of miRNA is changed in the diseased heart. They used to be recognized existing in cells only for some time, nevertheless, researches recently found that they are stable existence in human serum/plasma. Significantly, these circulating miRNAs can play as useful biomarkers for many diseases, including cancer, autoimmune diseases, tissue injury and other general clinical diseases. Besides, some researches have indicated that miRNAs serve an essential role in AMI. For example, miR-133a, miR-1 and miR-208 were proven to be cardio- or skeletal-muscle specific and enable to be used as biomarkers for the diagnosis of MI.
miR-499 Marker of Myocardial Infarction
Acute myocardial infarction (AMI) is a major cause of morbidity and mortality over the world, therefore, precise and efficient diagnostic biomarkers are required to help reduce the mortality of AMI patients. It is extensively accepted that a rapid and accurate diagnosis of AMI has a crucial impact on patients' treatment and prognosis. A recent study showed that MiR-499 was notably increased in 142 patients diagnosed with AMI by contrast to 85 patients in non-AMI group and 100 subjects in healthy control group. Meanwhile, plasma miR-499 was able to be measured as early as 1 h after onset of chest pain in AMI patients, and continued to increase without any sign of reduced tendency within 9 h. What's more, miR-499 was extremely positively associated with the serum cTnI and creatine kinase-MB (CK-MB). Thus, miR-499 may be a potential biomarker for early diagnosis of AMI.
Figure 1. In cardiomyocytes, the regulation of fusion/fission proteins results in mitochondrial fragmentation and cardiomyocyte apoptosis/MI. The expression of miR-499 and the downregulation of miR-140 enable to inhibit mitochondrial fission and apoptosis. (Duarte, F. V. 2014)
miR-499 Marker of Non-small Cell Lung Cancer
Lung cancer is the major cause of cancer-related mortality, among that non-small cell lung cancer (NSCLC) constitutes 85% of all lung cancer cases, and majority of the NSCLC patients display with advanced disease with a highly poor rate of cure. It is very important to find accurate and non-invasive biomarkers for the diagnosis, prognosis and prediction of recurrence to promote the clinical management of NSCLC patients. A recent research indicated that the expression of serum miR-499 was remarkably different between NSCLC patients and normal controls, implying that serum miR-499 level may be an available biomarker for the diagnosis, prognostic and prediction in patients with NSCLC.
Figure 2. miR-499-5p restrains NSCLC metastasis in vitro and in vivo. Graph A shows that miR-499-5p modulates E-cadherin and vimentin expression. Graph B shows the immunofluorescence analysis of E-cadherin and vimentin expression in A549 cells transfected with miR-499-5p or miR-499-5p inhibitor. (Li, M. 2016)
With the rapid development of IVD market, IVD antibodies are widely used for the diagnosis of a variety of diseases. Creative Biolabs offers various high-affinity IVD antibody development services for miR-499 marker to meet every customer's requirements. Creative Biolabs also provides other IVD antibodies. Please feel free to contact us for more information and a detailed quote.
For lab research use only.